Journal Watch · Nature Communications · 2026
Predicting trajectories of illness using RNA velocity of whole blood.
Our results demonstrate proof-of-concept for the use of RNA velocity to predict trajectories of human diseases.
TL;DR
Our results demonstrate proof-of-concept for the use of RNA velocity to predict trajectories of human diseases.
Key findings
- In individuals receiving biological therapy for inflammatory bowel disease, whole blood RNA velocity after the first dose of treatment indicates whether remission will be achieved by the end of the treatment course.
- In a multinational observational study of acutely unwell febrile children, VeloCD predicts those with greatest medical care requirements.
- Our results demonstrate proof-of-concept for the use of RNA velocity to predict trajectories of human diseases.
What they did
We developed VeloCD, a method for quantitative prediction of transitions in clinical state from a single time-point RNA sample. This predicts transcriptomic trajectories and future infection status in influenza A and SARS-CoV-2 controlled human infection studies, which are consistent with trajectories in naturally acquired infections. In HIV-TB coinfected individuals, VeloCD predicts the onset of immune reconstitution inflammatory syndrome.
Full abstract (original)
Background: Transcriptomic analyses reveal the status of cells, tissues, or organisms, across states of health and disease. RNA velocity adds a temporal dimension to single cell analyses, predicting future transcriptomic and phenotypic states, based on the current spliced and unspliced mRNA of each cell. We hypothesized that RNA velocity could be adapted to predict future clinical state of individuals with acute and chronic illnesses, using their whole-blood transcriptomes.
What they did: We developed VeloCD, a method for quantitative prediction of transitions in clinical state from a single time-point RNA sample. This predicts transcriptomic trajectories and future infection status in influenza A and SARS-CoV-2 controlled human infection studies, which are consistent with trajectories in naturally acquired infections. In HIV-TB coinfected individuals, VeloCD predicts the onset of immune reconstitution inflammatory syndrome.
Results & conclusions: In individuals receiving biological therapy for inflammatory bowel disease, whole blood RNA velocity after the first dose of treatment indicates whether remission will be achieved by the end of the treatment course. In a multinational observational study of acutely unwell febrile children, VeloCD predicts those with greatest medical care requirements. Our results demonstrate proof-of-concept for the use of RNA velocity to predict trajectories of human diseases.
Abstract © the authors / Nature Communications (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1038/s41467-026-71685-5 · PubMed 42091589.
Why it matters for pharma & biotech
- Directly relevant to teams in mRNA / delivery technology — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Modalities & themes detected: mRNA / delivery technology
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Nature Communications study find?
Our results demonstrate proof-of-concept for the use of RNA velocity to predict trajectories of human diseases.
What type of study is this?
It is a research study, published in Nature Communications in 2026. We developed VeloCD, a method for quantitative prediction of transitions in clinical state from a single time-point RNA sample.
Where can I read the original paper?
The original is at the publisher via DOI 10.1038/s41467-026-71685-5. PubMed ID: 42091589. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/predicting-trajectories-of-illness-using-rna-velocity-of-whole-blood-716855/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides